Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1Phase 4 1

Status

Completed 3Recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4Observational 1

Sponsor

Cancer Type

CNS 2Plasma cell 1Lymphoid 1

Conditions

Breast Neoplasms 2400Neoplasms 1819Carcinoma, Non-Small-Cell Lung 1599Prostatic Neoplasms 1298Colorectal Neoplasms 1140Lung Neoplasms 984Neoplasm Metastasis 830Multiple Myeloma 792Leukemia, Myeloid, Acute 767Ovarian Neoplasms 674Pancreatic Neoplasms 662Melanoma 660Squamous Cell Carcinoma of Head and Neck 586Carcinoma, Hepatocellular 567Recurrence 562Brain Neoplasms 527Glioblastoma 513Head and Neck Neoplasms 500Stomach Neoplasms 497Triple Negative Breast Neoplasms 465Lymphoma 454Uterine Cervical Neoplasms 450Carcinoma, Renal Cell 425Precursor Cell Lymphoblastic Leukemia-Lymphoma 410Lymphoma, Non-Hodgkin 389Endometrial Neoplasms 381Sarcoma 368Lymphoma, Follicular 356Urinary Bladder Neoplasms 354Hematologic Neoplasms 352

Interventions

Sodium Chloride 1Saline Solution 1Mn-PyC3A 1Dexmedetomidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Neuroinflammatory Diseases × 1 year × Clear all
NCT06745583 2026-06-03

A Phase 2 Study to Assess the Safety of EI-1071 and the Effects of EI-1071 on Neuroinflammation in Alzheimer's Disease Patients

Elixiron Immunotherapeutics (Hong Kong) Ltd.

Phase 2 Recruiting
15 enrolled
Lymphoid

Neuroinflammatory Diseases, Alzheimer Disease, Lymphoma, Follicular, Neurodegenerative Diseases, Cognitive Dysfunction

NCT07614243 2026-05-29

ZFAS1-BIPN

The First Affiliated Hospital of Zhejiang Chinese Medical University

Phase NA Completed
22 enrolled
Plasma cell

Neuroinflammatory Diseases, Multiple Myeloma

NCT04266665 2026-03-25

Effect of Dexmedetomidine on Brain Homeostasis and Neurocognitive Outcome

Aristotle University Of Thessaloniki

Phase 4 Completed
56 enrolled
CNS

Neuroinflammatory Diseases, Hypoxia, Brain Neoplasms

NCT06322342 2025-12-26

Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent

Reveal Pharmaceuticals Inc.

Phase 2 Completed
18 enrolled
CNS

Neuroinflammatory Diseases, Brain Neoplasms, Glioma, Meningioma, Multiple Sclerosis, Neoplasms, Neurilemmoma, Neurofibroma, Neuroma, Acoustic, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡